Ask AI
Latest evidence in obesity management

CE / CME

The Latest in Obesity Management: Current Evidence for Primary Care

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: September 25, 2025

Expiration: September 24, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Jay H. Shubrook, DO, FACOFP, FAAFP, discusses new developments related to obesity management, such as recent guidance on obesity definitions and diagnostic criteria. Dr Shubrook also discusses current evidence on incretin-based AOMs like semaglutide and tirzepatide, including information on their effects on obesity-related conditions/comorbidities, and on emerging therapies.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be downloaded here or by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

A 32-year-old man is in your office for a well-person check.
His height is 6′3″ (1.9 m), he weighs 254 lb (115 kg), and his BMI is 31.7 kg/m2. Based on recently published Lancet Diabetes & Endocrinology (Lancet) Commission definitions and diagnostic criteria, what can you conclude about this patient’s obesity status?

Your patient has clinical obesity and was receiving phentermine for weight loss when they were hospitalized for myocardial infarction. Which of the following reflects evidence on incretin-based antiobesity medications (AOMs) that should be considered when modifying your patient’s treatment?

Your patient agrees that an incretin-based AOM would be a good option for their obesity management. In addition to obesity, they have metabolic dysfunction–associated steatohepatitis (MASH) with moderate fibrosis and chronic kidney disease (CKD). Which AOM would you recommend to best address their overall health?

Your patient started a tirzepatide 15 mg prescription 1 year ago, and she has had a 19% weight loss. She is happy with her results so far, but her rate of weight loss has slowed, and she wonders if she should change to another agent to avoid weight regain and maintain her weight loss. How should you counsel her based on available evidence?

How many people with obesity do you provide care for in a typical week?

For those who practice in academic or community settings, please indicate your practice setting: